Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy, Immunotherapy.

Fox Chase Cancer Center, Philadelphia, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Philadelphia, PA
Treatments:Chemotherapy, ImmunotherapyHospital:Fox Chase Cancer Center
Drugs:Journal:Link
Date:Dec 2004

Description:

Patients:
This phase II study involved 31 patients with low-grade non-Hodgkin's lymphoma. The median patient age was 62 years and 15 were male.

Treatment:
Patients were treated with the chemotherapy agent fludarabine and the immunotherapy agent interferon-alpha (IFN), which stimulates the immune system to attack cancer cells.

Toxicity:
The most severe adverse events were of grade 4 and included anemia, lymphopenia, and thrombocytopenia. Fever, fatigue, and nausea were also reported.

Results:
The median overall survival was 60.8 months.

Support:
This study was partially supported by the pharmaceutical company Roche.

Correspondence: Dr. Mitchell R. Smith; email: m_smith@fccc.edu



Back